124 related articles for article (PubMed ID: 8438149)
1. Scripps-Sandoz deal comes under fire.
Anderson C
Science; 1993 Feb; 259(5097):889. PubMed ID: 8438149
[No Abstract] [Full Text] [Related]
2. Scripps to get less from Sandoz.
Anderson C
Science; 1994 May; 264(5162):1077. PubMed ID: 8178164
[No Abstract] [Full Text] [Related]
3. Scripps backs down on controversial Sandoz deal.
Anderson C
Science; 1993 Jun; 260(5116):1872-3. PubMed ID: 8316826
[No Abstract] [Full Text] [Related]
4. Intellectual property issues in a clinical trial: a corporate perspective.
Fersko RS; Connolly MJ
Qual Assur; 1992 Jun; 1(3):237-48. PubMed ID: 1344679
[No Abstract] [Full Text] [Related]
5. Grant proposal reviewer says he would have scored proposal lower due to conflict of interest.
Maloney DM
Hum Res Rep; 2004 Dec; 19(12):8. PubMed ID: 15810180
[No Abstract] [Full Text] [Related]
6. Health chief assails a research deal.
Hilts PJ
N Y Times Web; 1993 Mar; ():A12. PubMed ID: 11646979
[No Abstract] [Full Text] [Related]
7. Researcher said his colleague should have revealed possible conflicts of interest.
Maloney DM
Hum Res Rep; 2005 Jan; 20(1):8. PubMed ID: 15810184
[No Abstract] [Full Text] [Related]
8. What are we going to do with all that money?
Cohen JJ
Acad Med; 1998 May; 73(5):511. PubMed ID: 9609861
[No Abstract] [Full Text] [Related]
9. Terms of Scripps-Sandoz agreement may be more common than its critics believe.
Mervis J
Nature; 1993 Mar; 362(6417):194-5. PubMed ID: 8459840
[No Abstract] [Full Text] [Related]
10. Biomedical research in an era of unlimited aspirations and limited resources.
Fauci AS
Lancet; 1996 Oct; 348(9033):1002-3. PubMed ID: 8855860
[No Abstract] [Full Text] [Related]
11. Management operations of the National Cancer Institute that influence the governance of science.
Natl Cancer Inst Monogr; 1984 May; 64():1-139. PubMed ID: 6749243
[No Abstract] [Full Text] [Related]
12. Regulating scientific research: intellectual property rights and the norms of science.
Rai AK
Northwest Univ Law Rev; 1999; 94(1):77-152. PubMed ID: 12784815
[No Abstract] [Full Text] [Related]
13. Government-industry collaboration. NIH panel rejects pricing clause.
Anderson C
Science; 1994 Jul; 265(5172):598. PubMed ID: 8036506
[No Abstract] [Full Text] [Related]
14. Medical R&D at the turn of the millennium.
Zinner DE
Health Aff (Millwood); 2001; 20(5):202-9. PubMed ID: 11558704
[No Abstract] [Full Text] [Related]
15. NIH drops reasonable pricing clause.
Gavaghan H
Nature; 1995 Apr; 374(6524):669. PubMed ID: 7715715
[No Abstract] [Full Text] [Related]
16. NIH, FDA setting up research centers to generate evidence base to inform tobacco regulation.
Mitka M
JAMA; 2013 Oct; 310(15):1550. PubMed ID: 24129450
[No Abstract] [Full Text] [Related]
17. CTSA program continues 'on track' despite backlog.
Samson K
Ann Neurol; 2009 Sep; 66(3):A9-13. PubMed ID: 19810089
[No Abstract] [Full Text] [Related]
18. The role of US government agencies in vaccine research and development.
Folkers GK; Fauci AS
Nat Med; 1998 May; 4(5 Suppl):491-4. PubMed ID: 9585193
[No Abstract] [Full Text] [Related]
19. Lawmakers examine the possibility of favoritism in a $40-million NIH contract with Harvard.
Brainard J
Chron High Educ; 2003 Nov; 50(13):A19. PubMed ID: 15287136
[No Abstract] [Full Text] [Related]
20. Is academic medicine for sale?
Lebowitz J
N Engl J Med; 2000 Aug; 343(7):509; author reply 510. PubMed ID: 10950673
[No Abstract] [Full Text] [Related]
[Next] [New Search]
